Revolution Medicines, Inc.
Clinical trials sponsored by Revolution Medicines, Inc., explained in plain language.
-
New pill targets hard-to-treat cancers in early trial
Disease control OngoingThis early-phase study tests an experimental drug called RMC-6291 in adults with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to find a safe dose and see how the body processes the drug. About 222 people with lung, colorectal, or pancreatic cancer th…
Phase: PHASE1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 17, 2026 00:52 UTC
-
New hope for pancreatic cancer: targeted drug shows promise in Late-Stage trial
Disease control OngoingThis phase 3 study tests a new drug, daraxonrasib, against standard treatments in about 500 people with metastatic pancreatic cancer that has already been treated. The drug targets a specific genetic mutation (RAS) found in many pancreatic tumors. Researchers are measuring how lo…
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 17, 2026 00:51 UTC